VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Update

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a significant decrease in short interest in June. As of June 15th, there was short interest totaling 254,125 shares, a decrease of 34.7% from the May 31st total of 389,005 shares. Based on an average trading volume of 424,498 shares, the days-to-cover ratio is presently 0.6 days. Approximately 3.2% of the company’s shares are short sold.

VolitionRX Stock Performance

Shares of VolitionRX stock opened at $1.36 on Thursday. The firm has a market cap of $11.74 million, a PE ratio of -0.33 and a beta of 1.12. The business’s 50 day simple moving average is $2.12 and its 200 day simple moving average is $3.75. VolitionRX has a 52-week low of $1.17 and a 52-week high of $16.39.

VolitionRX (NYSEAMERICAN:VNRX) last released its quarterly earnings results on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.52 million. As a group, equities research analysts predict that VolitionRX will post -2.4 EPS for the current year.

Institutional Investors Weigh In On VolitionRX

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VNRX. Lagoda Investment Management L.P. grew its holdings in shares of VolitionRX by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after acquiring an additional 782,000 shares in the last quarter. Armistice Capital LLC raised its holdings in VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after acquiring an additional 887,351 shares in the last quarter. Geode Capital Management LLC raised its holdings in VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after acquiring an additional 85,816 shares in the last quarter. Citadel Advisors LLC boosted its position in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in VolitionRX during the fourth quarter valued at approximately $34,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on VNRX. Maxim Group reiterated a “buy” rating and set a $4.00 price objective on shares of VolitionRX in a report on Thursday, June 18th. HC Wainwright dropped their target price on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. Citigroup cut shares of VolitionRX to a “hold” rating in a report on Monday, April 20th. Finally, D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, VolitionRX presently has a consensus rating of “Hold” and a consensus target price of $28.00.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.